C2i, a genomics SaaS product to detect traces of cancer, raises $100M Series B –
Summary
If you or a loved one has ever undergone a tumor removal as part of cancer treatment, you’re likely familiar with the period of uncertainty and fear that follows. Every lab with a sequencing machine can process samples, upload to the C2i platform and provide detection and monitoring to the patient,” Zviran told TechCrunch. C2i Genomics’ solution is based on research performed at the New York Genome Center (NYGC) and Weill Cornell Medicine (WCM) by Dr. Zviran, along with Dr. Dan Landau, faculty member at the NYGC and assistant professor of medicine at WCM, who serves as scientific co-founder and member of C2i’s scientific advisory board. Zviran, who today has a PhD in molecular biology, was previously an engineer with the Israeli Defense Force and some private companies. Other investors that participated in the round include NFX, Duquesne Family Office, Section 32 (Singapore), iGlobe Partners and Driehaus Capital.